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Serum Phosphate
Concentrations
A Novel Pre-Clinical Biomarker
for Cardiovascular Calcification*
Nalini M. Rajamannan, MD
Chicago, Illinois
Calcific aortic valve disease is the most common indication
for surgical valve replacement in the United States. How-
ever, the number of patients that go undiagnosed is stag-
gering (1). During the past decade, the risk factors and
emerging methods of diagnosis are increasing rapidly as
novel therapeutic treatment modalities are evolving in the
21st century (2). In the paper by Linefsky et al. (3) in this
issue of the Journal, the investigators performed a stringent
analysis of the CHS (Cardiovascular Health Study) popu-
lation to determine if high-normal serum phosphate levels
are associated with 3 areas known to calcify with age: aortic
valve leaflet, mitral annulus, and aortic annulus. In this
study, the researchers demonstrated that high-normal se-
rum phosphate levels were increased in the aortic valve
leaflet (54%), mitral annulus (39%), and aortic annulus
(44%) without an association with serum calcium, parathy-
roid hormone, and 25-hydroxyvitamin D levels. This find-
ing correlates nicely with the growing scientific evidence in
the past 10 years demonstrating that this disease process is
an active mineralization process (3).
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The presence of calcification in the aortic valve is respon-
sible for valve stenosis (4). Severe aortic stenosis can result in
symptomatic chest pain, as well as syncope and congestive
heart failure in patients with severe aortic valve stenosis (5).
For years, aortic valve stenosis was thought to be a degen-
erative process. However, the pathological lesions of calci-
fied aortic valves indicate the presence of complex calcifica-
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Division of Cardiology, Department of Pathology, Northwestern
University Feinberg School of Medicine, Chicago, Illinois. Dr. Rajamannan receives
funding from the National Institutes of Health (5R01HL085591-04 and
3R01HL085591-02S1) and is an inventor on a patent for the use of statins in
degeneration of aortic valve disease. This patent is owned by the Mayo Clinic, and Dr.
Rajamannan does not receive any royalties from this patent.tion in these tissues and bone formation in the aortic valve
(6–9). Until recently, the etiology of valvular heart disease
has been thought to be a degenerative process related to the
passive accumulation of calcium binding to the surface of
the valve leaflet. Recent descriptive studies have demon-
strated the critical features of aortic valve calcification,
including osteoblast expression, bone cell phenotypes, cell
proliferation, and atherosclerosis (6,8,10,11). These studies
have defined the biochemical and histological characteriza-
tion of osteoblast-like bone formation in these valve lesions.
Stewart et al. (12) and Otto et al. (13) initially described
the risk factors for calcific aortic stenosis identified in the
CHS. The investigators examined 5,621 patients older than
65 years and found by Doppler echocardiography that the
prevalence of aortic valve sclerosis was 29% and aortic valve
stenosis was 2% in this population. The investigators dem-
onstrated that the clinical risk factors important for the
development of atherosclerosis are also independent risk
factors for aortic valve stenosis, including age, male sex,
height (inverse relationship), history of hypertension, smok-
ing, and elevated serum levels of lipoprotein(a) and low-
density lipoprotein (12). In this study by Linefsky et al. (3),
the investigators evaluated the 1992 or 1993 examinations
from the CHS population-based cohort study for an asso-
ciation of phosphate levels in the areas well known to
calcify, including the aortic valve leaflet, mitral annulus, and
aortic annulus. Serum phosphate, calcium, and parathyroid
hormone levels were measured. Lipid levels, glomerular
filtration rate, blood glucose levels, cystatin C levels, and
blood pressure were also measured. The presence of calcium
was identified using 2-dimensional echocardiography.
Interestingly, although the serum phosphate levels
correlated with cardiovascular calcification, they were also
directly proportional to the low-density lipoprotein levels
and inversely proportional to the glomerular filtration
rate. The most common cause of elevated levels of serum
phosphate is reduced urinary excretion with reduced renal
function (14). Understanding the spectrum of chronic
renal disease and cardiovascular calcification may contrib-
ute to the findings of this study. In vivo models of
vascular (15) and valvular calcification (16) are evolving
to test this hypothesis at the cellular level. Figure 1
demonstrates the paradox for bone-cardiovascular calci-
fication. This ongoing paradox between cardiovascular
calcification and osteoporosis has been under intense
investigation (17) for the past 15 years. This study
provides the next step in our understanding of this
paradox and the need for continued studies for patients
with both cardiovascular calcification and osteoporosis.
Identification of early valve sclerosis with a stethoscope,
multimodality imaging, and measurement of traditional
cardiovascular risk factors may help to identify early
preclinical disease in the heart and vasculature to risk-
stratify patients and modify cardiovascular risk factors
(18) in this patient population.
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